Veröffentlichungen in Zeitschriften Prof. Dr. Martin Deichmann

 

Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Hahn S, Pabst G, Voss D, Foguet M, Schmitz B, Lübbert H, Szeimies RM: Long-term (6 and 12 months) follow-up of two prospective, randomized, controlle phase III trials of photodynamic therapy with BF-200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis. British Journal of Dermatology 168: 825-836, 2013

 

Dirschka T, Radny P, Dominicus R, Mensing H, Brüning H, Jenne L, Karl L, Sebastian M, Oster-Schmidt C, Klövekorn W, Reinhold U, Tanner M, Gröne D, Deichmann M, Simon M, Hübinger F, Hofbauer G, Krähn-Senftleben G, Borrosch F, Reich K, Berking C, Wolf P, Lehmann P, Moers-Carpi M, Hönigsmann H, Wernicke-Panten K, Helwig C, Foguet M, Schmitz B, Lübbert H, Szeimies RM: Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis, results of a multicentre, randomized, observer-blind phase III study in comparison to a registered methyl-aminolaevulinic acid cream and placebo. British Journal of Dermatology 166: 137-146, 2012

 

Deichmann M: Shave-Exzisionen dysplastischer Nävuszellnävi, methodisches Vorgehen. Aktuelle Dermatologie 34: 279-281, 2008

 

Deichmann M, Krahl D, Thome M, Wüst K, Hassanzadeh J, Helmke B: The oncogenic B-raf  V599E mutation occurs more frequently in melanomas at sun-protected body sites. International Journal of Oncology 29: 139-145, 2006

 

Brennecke S, Deichmann M, Näher H, Kurzen H: Decline in angiongenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Research 15: 515-522, 2005

 

Deichmann M, Thome M, Egner U, Hartschuh W, Kurzen H: The chemoresistance gene ABCG2 (MXR/BCRP/ABCP1) is not expressed in melanomas but in single neuroendocrine carcinomas of the skin. Journal of Cutaneous Pathology 32: 467-473, 2005

 

Deichmann M, Thome M, Benner A, Kirschner M, Hassanzadeh J, Kurzen H: Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases. BMC Cancer 5: 58, 2005

 

Deichmann M, Huder JB, Kleist C, Näher H, Schüpbach J, Böni J: Detection of reverse transcriptase activity in human melanoma cell lines and identification of a murine leukemia virus contaminant. Archives of Dermatological Research 296: 345-352, 2005

 

Brennecke S, Deichmann M, Näher H, Kurzen H: Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Research 15: 515-522, 2005

 

Kirschner M, Helmke B, Starz H, Benner A, Thome M, Deichmann M: Preponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma lymph node metastases. Melanoma Research 15: 427-434, 2005

 

Helmke BM, Mollenhauer J, Herold-Mende C, Benner A, Thome M, Gassler N, Lyer S, Poustka A, Otto HF, Deichmann M: Rare BRAF mutations distinguish anorectal from cutaneous melanoma at molecular level. Gastroenterology 127: 1815-1820, 2004

 

Kurzen H, Berger H, Jäger C, Hartschuh W, Näher H, Gratchev A, Goerdt S, Deichmann M: Phenotypical and molecular profilinig of the extraneuronal cholinergic system of the skin. Journal of Investigative Dermatology 123: 937-949, 2004

 

Deichmann M: Journal Club, what is the best surgical treatment for anorectal melanoma? Coloproctology 26: 241-242, 2004

 

Helmke B, Polychronidis M, Benner A, Thome M, Arribas J, Deichmann M: Melanoma metastasis is associated with increased expression of the syntenin gene. Oncology Reports 12: 221-228, 2004

 

Deichmann M, Kahle B, Moser K, Wacker J, Wüst K: Diagnosing melanoma patients entering American Joint Committee on Cancer (AJCC) stage IV, C-reactive protein (CRP) in serum is superior to lactate dehydrogenase (LDH). British Journal of Cancer 91: 699-702, 2004

 

Deichmann M, Polychronidis M, Benner A, Kleist C, Thome M, Kahle B, Helmke B: Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. International Journal of Oncology 25: 259-268, 2004

 

Deichmann M, Thome M, Benner A, Näher H: B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome. Oncology 66:411-419, 2004

 

Deichmann M, Helmke B, Benner A, Thome M, Näher H: Somatic mitochondrial mutations in melanoma resection specimens. International Journal of Oncology 24: 137-141, 2004

 

Kurzen H, Kaul S, Egner U, Deichmann M, Hartschuh W: Expression of MUC1 and Ep-CAM in Merkel cell carcinomas, implications for immunotherapy. Archives of  Dermatological Research 295: 146-154, 2003

 

Mollenhauer J, Deichmann M, Helmke B, Müller H, Kollender G, Holmskov U, Ligtenberg T, Krebs I, Wiemann S, Bantel-Schaal U, Madsen J, Bikker F, Klauck SM Otto HF, Moldenhauer G, Poustka A: Frequent downregulation of DMBT1 and Galectin-3 in epithelial skin cancer. International Journal of Cancer 105: 149-157, 2003

 

Deichmann M, Kurzen H, Egner U, Altevogt P, Hartschuh W: Adhesion molecules CD171 (L1CAM) and CD24 are expressed by Merkel cell carcinomas but not in normal Merkel cells. Journal of Cutaneous Pathology 30: 363-368, 2003

 

Deichmann M, Thome M, Benner A, Egner U, Hartschuh W, Näher H: PTEN/MMAC1 expression in melanoma resection specimens. British Journal of Cancer 87: 1431-1436, 2002


Deichmann M:
Verlaufsbeobachtung des fernmetastasierten Melanoms mit der Laktatdehydrogenase und dem C-reaktiven Protein. Aktuelle Dermatologie 28: 290-296, 2002

 

Deichmann M, Mollenhauer J, Helmke B, Thome M, Hartschuh W, Poustka A, Näher H: Analysis of losses of heterozygosity of the candidate tumour suppressor gene DMBT1 in uncultured malignant melanomas. Oncology 63(2): 166-172, 2002

 

Waldmann V, Wacker J, Deichmann M: Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma. Melanoma Research 12 (1): 45-50, 2002

 

Deichmann M, Polychronidis M, Wacker J, Thome M, Näher H: The protein phosphatase 2A, subunit Bg, is identified to be differentially expressed in malignant melanomas by subtractive suppression hybridization. Melanoma Research 11: 577-585, 2001

 

Deichmann M, Benner A, Kuner N, Wacker J, Waldmann V, Näher H: Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100b or melanoma inhibitory activity (MIA)? Melanoma Research 11 (3): 291-296, 2001

 

Waldmann V, Wacker, J, Deichmann M: Mutations of the activation-associated phosphorylation sites at codons 308 and 473 of protein kinase B are absent in human melanoma. Archives of Dermatological Research 293 (7): 368-372, 2001

 

Waldmann V, Deichmann M, Jäckel A: Disseminierte Melanomzellen in Blut und Knochenmark, Bedeutung und Nachweis durch potentielle Tumormarker (Disseminated melanoma cells in blood and bone marrow, significance and detection by potential tumour markers). Hautarzt 52: 298-303, 2001

 

Jäckel A, Bock M, Deichmann M, Waldmann V, Näher H: Therapie des metastasierten malignen Uveamelanoms. Hautarzt 52: 98-103, 2001

 

Helmke BM, Deichmann M, Otto HF: Anorectal melanomas do not harbour the Kaposi’s sarcoma associated human herpesvirus type 8 DNA. Journal of Medical Virology 64: 47-50, 2001

 

Waldmann V, Goldschmidt, Jäckel A, Deichmann M, Hegenbart U, Hartschuh W, Ho A, Näher H: Transient complete remission of metastasized merkel cell carcinoma by high-dose polychemotherapy and autologous peripheral blood stem cell transplantation. British Journal of Dermatology 143: 837-839, 2000

 

Waldmann V, Wacker J, Deichmann M, Näher H: No correlation of tyrosinase mRNA in bone marrow with prognosis of metastatic melanoma. Dermatology 201: 6-9, 2000

 

Waldmann V, Wacker J, Deichmann M, Jäckel A, Bock M, Näher H: Prognosis of metastatic melanoma, no correlation of tyrosinase mRNA in bone marrow and survival time. Recent Results in Cancer Res. 158: 118-125, 2000

 

Deichmann M, Benner A, Jäckel A, Bock M, Waldmann V, Näher H: Elevated interleukin-6 serum levels indicate progressive disease in metastasized malignant melanoma. Journal of Experimental and Clinical Cancer Research 19: 301-307, 2000

 

Kahle B, Hummel S, Deichmann M, Petzoldt D: Bestimmung des Schweregrades einer venösen Insuffizienz mittels Duplex-Sonographie (Determining the severity of venous insufficiency with duplex sonography). Hautarzt 51: 70-74, 2000

 

Waldmann V, Bock M, Jäckel A, Deichmann M, Näher H: Pathogenese des malignen Melanoms, molekularbiologische Aspekte (Pathogenesis of malignant melanoma, molecular biology aspect). Hautarzt 50: 398-405, 1999

 

Waldmann V, Deichmann M, Bock M, Jäckel A, Näher H: The detection of tyrosinase-specific mRNA in bone marrow is not more sensitive than in blood for the demonstration of micrometastatic melanoma. British Journal of Dermatology 140: 1060-1064, 1999

 

Jäckel A, Deichmann M, Waldmann V, Bock M, Näher H: Regression of a metastatic angiosarcoma of the skin after systemic treatment with liposome-encapsulated doxorubicin and interferon-a. British Journal of Dermatology 140: 1187-1188, 1999 (letter)

 

Deichmann M, Benner A, Bock M, Jäckel A, Waldmann V, Uhl K, Näher H: S100b, MIA and LDH discriminate progressive from non-progressive AJCC stage IV melanoma disease. Journal of Clinical Oncology 17: 1891-1896, 1999

 

Deichmann M, Thome M, Bock M, Jäckel A, Waldmann V, Näher H: The human herpesvirus-type 8 DNA is not involved in malignant melanoma. British Journal of Cancer 80: 67-69, 1999

 

Jäckel A, Deichmann M, Waldmann, Bock M, Näher H: S-100b als Tumormarker beim malignen Melanom – Aktueller Kenntnisstand und klinische Erfahrungen (S-100b protein in serum, a tumour marker in malignant melanoma, current state of knowledge and experiences). Hautarzt 50: 250-256, 1999

 

Bock M, Deichmann M, Waldmann V, Jäckel A, Näher A: Mycosis fungoides und Sezary-Syndrom, anhaltende Remissionen durch die Kombination von extrakorporaler Photopherese und Interferon-a. Aktuelle Dermatologie 25: 15-20, 1999

 

Deichmann M, Thome M, Jäckel A, Utermann S, Bock M, Waldmann V, Näher H: Non-human immunodeficiency virus Kaposi’s sarcoma can be effectively treated with low-dose interferon-alpha despite persistance of herpesvirus-8. British Journal of Dermatology 139 (6): 1052-1054, 1998

 

Viadot A, Kronenwett R, Deichmann M, Haas R: The human immunodeficiency virus (HIV)-type 1 coreceptor CXCR-4 (fusin) is preferentially expressed on the more immature CD34+ hematopoietic stem cells. Annals of Hematology 77(5): 193-197, 1998

 

Deichmann M, Helmke B, Bock M, Jäckel A, Waldmann V, Flechtenmacher C, Zoubaa S, Näher H: Massive lethal cerebral bleeding in a melanoma patient without intracranial metastasis. Clinical Oncology 10(4): 272-273, 1998

 

Deichmann M, Kronenwett R, Haas R: Expression of the human immunodeficiency virus typte-1 coreceptors CXCR-4 (fusin, LESTR) and CKR-5 in CD34+ hematopoietic progenitor cells. Blood 89: 3522-3528, 1997

 

Deichmann M, Sczakiel G, Haas R: Disinfection of intra- and extracellular HIV-1 by PUVA treatment. Journal of Virological Methods 68(1): 89-95, 1997

 

Deichmann M, Bentz M, Haas R: Ultra-sensitive FISH is a uselful tool in studying chronic HIV-1 infection. Journal of Virological Methods 65(1): 19-25, 1997